Drugs / Chimeric antigen receptor T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04691349 | Sep 2020 → Jan 2021 | cancer | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chimeric antigen receptor T cells | “Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors).” NCT04691349 ↗ |
| Known as | car-t | “Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors).” NCT04691349 ↗ |
| Action | Deplete | “use the patient's own immune cells to clear cancer cells” NCT04691349 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T cells (car-t)” NCT04691349 ↗ |